Imaging features of intestinal metastasis from pulmonary sarcomatoid carcinoma

Background: the aim of this study was to examine the imaging features of patients diagnosed with pulmonary sarcoma (psc) exhibiting small bowel metastases, utilizing magnetic resonance imaging (mri) and computed tomography (ct), and to report the clinical outcomes of surgical resection in conjunction with duvacizumab drug therapy. materials and methods: clinical data and ct imaging markers of patients with pathologically confirmed primary pulmonary sarcoma from january 2020 to april 2021 were retrospectively assessed. results: immunohistochemical analysis of lung tissue samples indicated galectin-3(+), pas(-), myoglobin(-), f8(-), cd31(-), ttf(+), p40 (-), d2-40(-), hmb45(-), ae1/ae3(+), mc(-), and cd68(-). pd-l1 positive cell count, as determined through immunohistochemical evaluation, was 50%. immunohistochemical findings of the patient's small intestine tissue revealed ae1/ae3 (+), cd117(-), cd34(-), desmin(-), sma(-), vimentin(+), s-100(-), ck7(-), ck20(-), cea(-), ema(-), pas(-), cd45(-), with a ki-67 positivity rate of approximately 40%. following 11 cycles of duvacizumab drug therapy, the volume of the patient's left upper lung mass decreased from 7.1 cm × 5.7 cm to 2.8 cm x 3.3 cm. conclusion: the combination of surgical resection and duvacizumab drug therapy demonstrated clinical efficacy in patients with psc and holds promise as a potential treatment option for patients suffering from psc.